Veeva and Sarah Cannon Research Institute Form Strategic Collaboration to Advance Oncology Clinical Trials

Rhea-AI Summary

Veeva Systems (NYSE: VEEV) and Sarah Cannon Research Institute (SCRI) have announced a strategic collaboration to enhance oncology clinical trials across SCRI's 200+ research sites. SCRI is implementing Veeva Clinical Platform to unify its contract research organization (CRO) and site management organization (SMO) operations. The platform will streamline data flow between clinical teams and research sites, standardize trial processes, and enable automation of key processes. This first-of-its-kind partnership aims to improve efficiency, speed, and cost-effectiveness in oncology research by providing a unified foundation for clinical trials.

Positive

• Strategic partnership with major oncology research organization SCRI expands Veeva's market presence
• Integration across 200+ research sites increases platform adoption and potential revenue
• First-of-its-kind partnership demonstrates Veeva's leadership in clinical trial technology
• Platform implementation expected to improve operational efficiency and reduce costs

Negative

• None.

News Market Reaction

-0.41%

1 alert

-0.41% News Effect

On the day this news was published, VEEV declined 0.41%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Leading oncology research organization adopts Veeva Clinical Platform to enhance study delivery

PLEASANTON, Calif. and NASHVILLE, Tenn., June 4, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) and Sarah Cannon Research Institute (SCRI) today announced a strategic collaboration to drive speed and efficiency in oncology clinical trials across SCRI's more than 200 research site locations. SCRI is adopting Veeva Clinical Platform to unify its contract research organization (CRO) and site management organization (SMO) on a single platform for seamless data flow across clinical teams and research sites.

"We are thrilled to advance our clinical trials by integrating Veeva Clinical Platform into our digital toolkit," said SCRI chief information and digital officer Yazhene Krishnaraj. "This strategic collaboration empowers our clinical teams to deliver groundbreaking therapies to patients with enhanced precision and speed."

Veeva Clinical Platform will enable SCRI to simplify and standardize trial processes and information flow, improving how investigators and clinical teams work together and share data. With a connected foundation for clinical research, SCRI will be able to automate key processes and provide a streamlined experience for its sites.

"We're excited to work closely with SCRI to drive innovation in oncology research," said Jim Reilly, president of Veeva Development Cloud. "In a first-of-a-kind partnership, Veeva Clinical Platform will serve as SCRI's clinical trial foundation for its CRO and SMO. By standardizing operations on one platform, we can support SCRI in delivering faster and more cost-effective trials."

About Veeva Clinical Platform
Veeva Clinical Platform is a complete and connected platform across clinical operations and data applications. This end-to-end platform includes CTMS, EDC, clinical workbench (CDB), RTSM, eCOA, eTMF, Site Connect, Study Training, and more. Connected products streamline clinical trials from study start-up to close and automate a connected data flow. To learn more about Veeva Clinical Platform, visit veeva.com/VeevaClinicalPlatform.

About Sarah Cannon Research Institute
Sarah Cannon Research Institute (SCRI) is one of the world's leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted more than 850 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA in the past decade. SCRI's research network brings together more than 1,300 physicians who are enrolling patients to clinical trials at over 200 locations in more than 20 states across the U.S. Visit SCRI.com to learn more.

About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's strategic collaboration with SCRI and the expected results or benefits from such collaboration. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended April 30, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 32 and 33), and in our subsequent SEC filings, which you can access at sec.gov.

Contact:
Veeva Deivis Mercado                               925-226-8821 deivis.mercado@veeva.com	SCRI Becca Gelman Becca.Gelman@scri.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/veeva-and-sarah-cannon-research-institute-form-strategic-collaboration-to-advance-oncology-clinical-trials-302472592.html

SOURCE Veeva Systems

FAQ

What is the strategic collaboration between Veeva Systems (VEEV) and Sarah Cannon Research Institute?

Veeva and SCRI are collaborating to enhance oncology clinical trials by implementing Veeva Clinical Platform across SCRI's 200+ research sites, unifying their CRO and SMO operations on a single platform.

How many research sites will implement Veeva's Clinical Platform through the SCRI partnership?

The Veeva Clinical Platform will be implemented across more than 200 Sarah Cannon Research Institute research site locations.

What are the main benefits of the Veeva-SCRI collaboration for clinical trials?

The collaboration aims to improve speed, efficiency, and cost-effectiveness in oncology clinical trials by standardizing processes, enabling automation, and providing seamless data flow across clinical teams and research sites.

How will the Veeva Clinical Platform impact SCRI's operations?

The platform will unify SCRI's CRO and SMO operations, simplify and standardize trial processes, improve collaboration between investigators and clinical teams, and provide a streamlined experience for research sites.

What makes the Veeva-SCRI partnership unique in clinical research?

It is a first-of-its-kind partnership where Veeva Clinical Platform will serve as the foundation for both CRO and SMO operations at a major research institution.